Breakthrough Study Makes Cancer Detection Possible With a Simple Blood Test; Introduces a New Systemic Hallmark of Cancer

PR82778

MUMBAI, India, Feb. 5, 2020 /PRNewswire=KYODO JBN/ --

- The new study by Datar Cancer Genetics(https://datarpgx.com/) has used a revolutionary

new method that detects clusters of tumor cells circulating in the bloodstream and helps in

early detection of cancer

- The paper is titled ''Circulating ensembles of tumor-associated cells:

A redoubtable new systemic hallmark of cancer" and has been published in

the International Journal of Cancer (https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32815 ).

    A new study (https://onlinelibrary.wiley.com/doi/epdf/10.1002/ijc.32815 )

by scientists from India, USA, and UK has presented clinical evidence for an innovative test

that can detect clusters of cancer cells in the blood of asymptomatic individuals as a non-invasive

screening and diagnostic test. The test could make cancer screening easier, efficient and

affordable, and can potentially be a breakthrough in cancer detection and diagnosis.

The test will soon be available commercially.

    Commenting on the study, principal author Dr. Dadasaheb Akolkar, who is

the Research Director at Datar Cancer Genetics, said, "This is the first study of

its kind to investigate the prevalence of circulating tumor emboli or C-ETACs

(Circulating Ensembles of Tumor Associated Cells), in a population size cohort

of over 16,000 participants, to establish a definitive new systemic hallmark of

cancer. The technique we have used is a breakthrough innovation. When clusters

of cells break off from an early stage tumor and enter the bloodstream we can

efficiently and accurately isolate a few hundred malignant cells from more than

100 million cells, from just 10 ml of blood. While almost all the cancer samples

had these cell clusters, they were seen in very few of the samples which were

apparently without cancer."

    Speaking on the breakthrough study and technique, Mr. Rajan Datar, Chairman

and Managing Director, Datar Cancer Genetics, said, "Cancer is rapidly becoming

a civilizational challenge. Importantly, cancer deaths are mainly due to late detection.

We believe that this innovative blood based test is a breakthrough in cancer screening

and will impact outcomes by easy, patient-friendly detection and diagnosis in apparently

healthy people who may have a silent malignancy in their bodies! It has the potential

to eliminate the need for invasive biopsies and the risks associated with it. In the near future,

a simple, inexpensive blood test that could be all that is required to reliably detect and

diagnose cancer, even before any symptoms are seen."

    The study involved 16,134 participants, including 5,509 patients with

cancer (TrueBlood study) and 10,625 individuals with no symptoms (RESOLUTE

study) and the test has shown an accuracy of more than 94%. The C-ETACs were

seen in 89.8% of cancer cases and in only 3% of apparently healthy, asymptomatic

individuals who had no abnormal findings in presently used screening tests.

The study was the largest of its kind in the world.

    Datar Cancer Genetics also presented further data at several leading

international conferences including AACR, ASCO and ESMO

(https://datarpgx.com/trublood-publications/ )

    Early detection of cancer is crucial but challenging, because of the lack

of efficient and reliable screening methods. Most of the commercially available

cancer-screening tests are invasive and expensive. Also, currently available

cancer screening techniques such as mammograms and low-dose CT scans (LDCT)

carry radiation risks, colonoscopies are invasive, blood based markers are non-specific

and tissue biopsies for diagnosis have the same risks as general surgical procedures.

    Datar Cancer Genetics (https://datarpgx.com/) is a world leading CAP and CLIA accredited

cancer Solutions Company developing non-invasive tests for better cancer management.

    Links:

    https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.32815

    https://datarpgx.com/trublood-publications/

    https://datarpgx.com/

    For more information contact:

    Dr. Vineet Datta

    MD MRCP(UK) FRCP(Glasg)

    FIMSA MRCEM

    FRSPH CMQ/OE ASQ

    Executive Director

    Datar Cancer Genetics Limited

    E-mail: drvineetdatta@datarpgx.com

    Logo:

    https://mma.prnewswire.com/media/1086492/Datar_Cancer_Genetics_Logo.jpg

    Photo: https://mma.prnewswire.com/media/1086493/Cancer_detection.jpg

    Source: Datar Cancer Genetics Ltd